Head-to-head evidence
tildrakizumab vs ustekinumab-ttwe (Pyzchiva)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries
NCT04314544 · Phase 3 · completed
The study randomized 508 participants to tildrakizumab or placebo, with outcome assessors masked, and used the clinical ACR20 response as its primary endpoint. However, no results are posted, so whether the primary endpoint was met or missed is unknown.
Next expected readout: December 2028 · NCT04991116 (registry estimate)
ustekinumab-ttwe (Pyzchiva)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tildrakizumab's landscape · ustekinumab-ttwe (Pyzchiva)'s landscape